China based The United Laboratories International Holdings Limited (TUL) and Danish pharmaceutical company Nov
GSK Singapore has announced that Omjjara (momelotinib) has been locally approved for treatment of disease-rela
British pharmaceutical company AstraZeneca has announced an investment of $2.5 billion in Beijing to establish
University of Queensland researchers are designing nanotechnology they believe could improve how we treat the
A new ‘nanoball’ vaccine platform developed by experts in Japan will be tested as part of new rese
Taiwan-based Formosa Group Executive Committee member and Chairman Sandy Wang, who leads the group's bio and e
The Ministry of Health in Egypt has signed a Memorandum of Understanding (MoU) with Siemens Healthineers on to
ABL Diagnostics, a Euronext-listed leader in molecular diagnostics, has announced an exclusive distribution ag
Novotech, a global leading full-service clinical Contract Research Organization (CRO), and Acrostar, a provide
Avance Clinical, a leading full-service global Contract Research Organization (CRO) specialising in high-quali
Mitigating PATENT CLIFF Fallout
Monoclonal antibodies (mAbs) represent a $279.8 billion market, projected to reach $804 billion by 2033, according to a report from Dimension Market Research. With patents for many of these valuable drugs set to expire in the coming years, the industry faces significant challenges. In this story, we examine 11 blockbuster mAbs whose patents will expire between 2025 and 2030. These expirations, affecting some of pharma's biggest players, will have a major impact on the market and their revenue streams.
ISPOR 2025
ISPOR
info@ispor.org https://www.ispor.org/conferences-education/event/2025/05/13/default-calendar/ispor-2025Montreal
Immuno-Oncology 360° 2025
The conference forum
service@tcfllc.org https://io360summit.com/agenda/Boston
5th European Conference on Pharmaceutics 2025
ApV
info@apv-mainz.de https://www.apv-mainz.de/en/events/details/artikel/5th-european-conference-on-pharmaceutics.htmlPorto